FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103132902> ?p ?o ?g. }

• W2103132902 endingPage "413" @default.
• W2103132902 startingPage "399" @default.
• W2103132902 abstract "Véronique Mathieu 1,* , Christine Pirker 2,3,* , Wolfgang M. Schmidt 4 , Sabine Spiegl-Kreinecker 5 , Daniela Lötsch 2,3 , Petra Heffeter 2,3 , Balazs Hegedus 3,6,7 , Michael Grusch 2,3 , Robert Kiss 1 , and Walter Berger 2,3 1 Laboratory of Toxicology, Faculty of Pharmacy, Université Libre de Bruxelles, Brussels, Belgium 2 Department of Medicine I, Institute of Cancer Research, Medical University Vienna, Vienna, Austria 3 Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria 4 Neuromuscular Research Department, Center for Anatomy and Cell Biology, Medical University Vienna, Vienna, Austria 5 Department of Neurosurgery, Landesnervenklinik Wagner-Jauregg Hospital, Linz, Austria 6 Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria 7 2nd Institute of Pathology, Semmelweis University, Budapest, Hungary * Denotes equal contribution Received: March 30, 2012; Accepted: April 20, 2012; Published: April 24, 2012; Keywords: malignant melanoma, aneuploidy, local aggressiveness, xenograft, integrative genomics Correspondence: Walter Berger, email: // // Abstract Melanoma is a devastating skin cancer characterized by distinct biological subtypes. Besides frequent mutations in growth- and survival-promoting genes like BRAF and NRAS , melanomas additionally harbor complex non-random genomic alterations. Using an integrative approach, we have analysed genomic and gene expression changes in human melanoma cell lines (N=32) derived from primary tumors and various metastatic sites and investigated the relation to local growth aggressiveness as xenografts in immuno-compromised mice (N=22). Although the vast majority (>90%) of melanoma models harbored mutations in either BRAF or NRAS , significant differences in subcutaneous growth aggressiveness became obvious. Unsupervised clustering revealed that genomic alterations rather than gene expression data reflected this aggressive phenotype, while no association with histology, stage or metastatic site of the original melanoma was found. Genomic clustering allowed separation of melanoma models into two subgroups with differing local growth aggressiveness in vivo . Regarding genes expressed at significantly altered levels between these subgroups, a surprising correlation with the respective gene doses (>85% accordance) was found. Genes deregulated at the DNA and mRNA level included well-known cancer genes partly already linked to melanoma ( RAS genes, PTEN , AURKA , MAPK inhibitors Sprouty/Spred), but also novel candidates like SIPA1 (a Rap1GAP). Pathway mining further supported deregulation of Rap1 signaling in the aggressive subgroup e.g. by additional repression of two Rap1GEFs. Accordingly, siRNA-mediated down-regulation of SIPA1 exerted significant effects on clonogenicity, adherence and migration in aggressive melanoma models. Together our data suggest that an aneuploidy-driven gene expression deregulation drives local aggressiveness in human melanoma." @default.
• W2103132902 created "2016-06-24" @default.
• W2103132902 creator A5012933847 @default.
• W2103132902 creator A5032882550 @default.
• W2103132902 creator A5033125669 @default.
• W2103132902 creator A5033593586 @default.
• W2103132902 creator A5033613763 @default.
• W2103132902 creator A5043913136 @default.
• W2103132902 creator A5053342008 @default.
• W2103132902 creator A5059704501 @default.
• W2103132902 creator A5071324605 @default.
• W2103132902 creator A5081535653 @default.
• W2103132902 date "2012-04-24" @default.
• W2103132902 modified "2023-10-18" @default.
• W2103132902 title "Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation" @default.
• W2103132902 cites W1948224603 @default.
• W2103132902 cites W1965540910 @default.
• W2103132902 cites W1968667083 @default.
• W2103132902 cites W1984362855 @default.
• W2103132902 cites W1989121777 @default.
• W2103132902 cites W1990713277 @default.
• W2103132902 cites W2001256555 @default.
• W2103132902 cites W2002195822 @default.
• W2103132902 cites W2002682475 @default.
• W2103132902 cites W2003840902 @default.
• W2103132902 cites W2007359193 @default.
• W2103132902 cites W2012806962 @default.
• W2103132902 cites W2012906168 @default.
• W2103132902 cites W2013977169 @default.
• W2103132902 cites W2018117935 @default.
• W2103132902 cites W2034550661 @default.
• W2103132902 cites W2049002285 @default.
• W2103132902 cites W2054363302 @default.
• W2103132902 cites W2064641360 @default.
• W2103132902 cites W2065465102 @default.
• W2103132902 cites W2065775098 @default.
• W2103132902 cites W2067605044 @default.
• W2103132902 cites W2071596809 @default.
• W2103132902 cites W2079118647 @default.
• W2103132902 cites W2079281248 @default.
• W2103132902 cites W2081015231 @default.
• W2103132902 cites W2082378464 @default.
• W2103132902 cites W2085017455 @default.
• W2103132902 cites W2088022023 @default.
• W2103132902 cites W2090420216 @default.
• W2103132902 cites W2096020932 @default.
• W2103132902 cites W2106304591 @default.
• W2103132902 cites W2110466396 @default.
• W2103132902 cites W2122036933 @default.
• W2103132902 cites W2122769974 @default.
• W2103132902 cites W2124950448 @default.
• W2103132902 cites W2132757816 @default.
• W2103132902 cites W2141277115 @default.
• W2103132902 cites W2149688672 @default.
• W2103132902 cites W2150852167 @default.
• W2103132902 cites W2152315800 @default.
• W2103132902 cites W2158293024 @default.
• W2103132902 cites W2158734599 @default.
• W2103132902 cites W2158792942 @default.
• W2103132902 cites W2160697532 @default.
• W2103132902 cites W2161275429 @default.
• W2103132902 cites W2170984819 @default.
• W2103132902 cites W2171844034 @default.
• W2103132902 cites W4244068819 @default.
• W2103132902 doi "https://doi.org/10.18632/oncotarget.473" @default.
• W2103132902 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3380575" @default.
• W2103132902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22535842" @default.
• W2103132902 hasPublicationYear "2012" @default.
• W2103132902 type Work @default.
• W2103132902 sameAs 2103132902 @default.
• W2103132902 citedByCount "54" @default.
• W2103132902 countsByYear W21031329022012 @default.
• W2103132902 countsByYear W21031329022013 @default.
• W2103132902 countsByYear W21031329022014 @default.
• W2103132902 countsByYear W21031329022015 @default.
• W2103132902 countsByYear W21031329022016 @default.
• W2103132902 countsByYear W21031329022017 @default.
• W2103132902 countsByYear W21031329022018 @default.
• W2103132902 countsByYear W21031329022019 @default.
• W2103132902 countsByYear W21031329022020 @default.
• W2103132902 countsByYear W21031329022021 @default.
• W2103132902 countsByYear W21031329022022 @default.
• W2103132902 countsByYear W21031329022023 @default.
• W2103132902 crossrefType "journal-article" @default.
• W2103132902 hasAuthorship W2103132902A5012933847 @default.
• W2103132902 hasAuthorship W2103132902A5032882550 @default.
• W2103132902 hasAuthorship W2103132902A5033125669 @default.
• W2103132902 hasAuthorship W2103132902A5033593586 @default.
• W2103132902 hasAuthorship W2103132902A5033613763 @default.
• W2103132902 hasAuthorship W2103132902A5043913136 @default.
• W2103132902 hasAuthorship W2103132902A5053342008 @default.
• W2103132902 hasAuthorship W2103132902A5059704501 @default.
• W2103132902 hasAuthorship W2103132902A5071324605 @default.
• W2103132902 hasAuthorship W2103132902A5081535653 @default.
• W2103132902 hasBestOaLocation W21031329021 @default.
• W2103132902 hasConcept C104317684 @default.
• W2103132902 hasConcept C121608353 @default.
• W2103132902 hasConcept C126322002 @default.

• next